Six months, one egg, and the allergy panic that won't quit

There is a familiar choreography to nutrition news in 2026. A study lands, a headline compresses it, an app pushes it to a phone, and a parent staring at a six-month-old at breakfast has to decide whether the soft scramble in front of the child is medicine or menace. The latest instalment, reported on 15 June 2026 by The Indian Express, follows the form. Introducing eggs to infants at around six months, the coverage says, is associated with a 17 percent reduction in egg-allergy risk. The number is precise enough to be useful and small enough to be ignored. Neither outcome is likely.

The 17 percent figure is the kind of marginal result that gets reified into a mandate within a news cycle. It sits inside a much larger body of work — the LEAP study on peanuts, the EAT trial, a decade of meta-analyses — that has collectively demolished the old orthodoxy of strict delay. That older orthodoxy was not cautious; it was wrong, and it produced a generation of American and European infants whose immune systems were never properly taught the difference between food and threat. The new finding is part of the slow correction. But the correction is arriving into a media environment that still defaults to risk, still treats every feeding choice as a referendum on parental virtue, and still cannot tell the difference between a relative risk reduction and a moral injunction.

The deeper problem is upstream of any single study. Public-health communication in most major markets treats parents as a population to be managed rather than adults to be informed. A 17 percent relative reduction in a condition that affects a small minority of infants becomes, in this register, an obligation: every parent who fails to comply is a data point in someone else's ledger. The Indian Express piece is responsible — it reports the figure, it names the framing, it stops short of sermonising. The same cannot be said of the broader ecosystem, in which an Instagram reel and a refereed paper are forced to compete on equal terms for the same panicked three seconds of attention.

The Global South framing here matters more than the wire services will admit. The Indian Express coverage is part of a slow shift in the centre of gravity of nutrition science away from North Atlantic teaching hospitals and toward South Asian, East Asian, and Latin American cohorts whose infants have eaten eggs, peanuts, fish and shellfish as first foods for generations. The allergy panic was always, at heart, an artefact of wealthy, low-microbial, over-sanitised childhoods being projected onto the rest of the world as a universal template. When Indian researchers confirm the obvious — that early exposure works, that the immune system is a learning organ, that food is the curriculum — they are not breaking news. They are restating, in cleaner statistics, what a hundred grandmothers in Tamil Nadu, Punjab and Kerala never had to be told.

That is the structural point the mainstream coverage will miss. Nutrition science is still institutionally organised around the assumption that the developed-world infant is the default infant, and that evidence from elsewhere is supplementary. The opposite is closer to true. The allergy epidemic is a developed-world pathology, produced by the specific concatenation of caesarean delivery, antibiotic overuse, ultra-clean homes, and the delayed-introduction advice itself. The 17 percent figure matters, but the cohort it was generated in is not the cohort that most needs the message. The audiences in Delhi, Lagos, Lima and Jakarta already feed their babies eggs. They are not the at-risk population for a return to delay; the at-risk population is in Boston and Berlin and Brisbane, where the old advice has done the most damage and where the new advice will be the slowest to land.

The stakes, then, are not really about eggs. They are about whether public-health communication is capable of admitting a mistake on this kind of scale, in real time, without burying the correction in jargon. The peanut and egg evidence has been building for fifteen years. The clinical guidance is moving, slowly, in the right direction. The popular press, the parenting-influencer economy, and the apps that monetise anxiety are moving much more slowly, because correction is bad for engagement. A 17 percent reduction in allergy risk is, in the end, a small number doing very heavy lifting. The lift it needs to do is not biological. It is institutional — an admission, broadcast clearly, that a generation of parents were told to fear exactly the foods that would have protected their children.

What remains uncertain is whether the next round of coverage will say so plainly, or whether the 17 percent will be laundered into another consumer product — a fortified infant pouch, a subscription service, a wearable that measures the immune consequences of breakfast. The study is solid. The communication apparatus it now enters is not.

Desk note: Monexus reports the Indian Express coverage as filed and pushes back, in this column, against the risk-amplification reflex that has dominated English-language nutrition journalism for two decades.